Currencies / LGND
LGND: Ligand Pharmaceuticals Incorporated
161.71
USD
1.75
(1.09%)
LGND exchange rate has changed by 1.09% for today. During the day, the instrument was traded at a low of 160.05 and at a high of 163.34.
Follow Ligand Pharmaceuticals Incorporated dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
LGND News
- Ligand Pharmaceuticals stock hits 52-week high at 161.93 USD
- Ligand Pharma stock price target raised to $206 from $157 at H.C. Wainwright
- Ligand Pharmaceuticals stock hits 52-week high at $157.54
- Orchestra BioMed stock rating downgraded to Neutral from Buy by BTIG
- Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced
- Ligand Pharmaceuticals completes $460 million convertible notes offering
- Ligand Pharmaceuticals prices $400 million convertible notes offering
- Ligand Pharmaceuticals plans $400 million convertible notes offering
- Ligand Pharma stock price target raised to $185 from $155 at RBC Capital
- Ligand Pharma stock price target raised to $167 by Oppenheimer on strong royalty growth
- Ligand (LGND) Q2 Revenue Jumps 15%
- Ligand Q2 2025 presentation: 57% royalty growth drives raised guidance
- Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD
- Stock Market Week Ahead: Caterpillar, Palantir And Black Hat Week
- Orchestra BioMed secures $70 million from Ligand and Medtronic
- Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth
- Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target
- Ligand Pharmaceuticals Stock Earns 84 RS Rating
- Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD
- Ligand Pharmaceuticals director Kozarich sells $116k in stock
- Why Is Pelthos Therapeutics Stock Trading Higher Thursday - Pelthos Therapeutics (AMEX:PTHS)
- Ligand earns $5 million milestone as partner launches molluscum treatment
- Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - First Majestic Silver (NYSE:AG), AES (NYSE:AES)
- Ligand completes merger, Pelthos to launch molluscum treatment
Daily Range
160.05
163.34
Year Range
93.58
163.34
- Previous Close
- 159.96
- Open
- 161.35
- Bid
- 161.71
- Ask
- 162.01
- Low
- 160.05
- High
- 163.34
- Volume
- 301
- Daily Change
- 1.09%
- Month Change
- 23.55%
- 6 Months Change
- 29.19%
- Year Change
- 52.83%
31 August, Sunday